Clindamycin (hydrochloride monohydrate)

• UNSPSC Description:

  Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla)[1].

• Target Antigen:

  Antibiotic; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/clindamycin-hydrochloride-monohydrate.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCC[C@H]1CN(C)[C@H](C(N[C@]([C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)([H])[C@H](C)Cl)=O)C1.[H]Cl.[H]O[H]

• Molecular Weight:

  479.46

• References & Citations:

  [1]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17(1):38.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  58207-19-5